EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Blockers of Skeletal Muscle Nav1.4 Channels: From Therapy of Myotonic Syndrome to Molecular Determinants of Pharmacological Action and Back

Michela De Bellis, Brigida Boccanegra iD, Alessandro Giovanni Cerchiara, Paola Imbrici iD, Annamaria De Luca iD

International Journal of Molecular Sciences · 2023

DOI: 10.3390/ijms24010857 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Michela De Bellis und 4 weiteren Autor:innen. Beteiligte Einrichtung: Section of Pharmacology, Department of Pharmacy-Drug Sciences, University of Bari "Aldo Moro", 70125 Bari, Italy. Hauptthemen laut MEDLINE: Mexiletine, Myotonia, NAV1.4 Voltage-Gated Sodium Channel, Voltage-Gated Sodium Channel Blockers. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 110 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: PRIN 2017, Ateneo Uniba, PRIN.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The voltage-gated sodium channels represent an important target for drug discovery since a large number of physiological processes are regulated by these channels. In several excitability disorders, including epilepsy, cardiac arrhythmias, chronic pain, and non-dystrophic myotonia, blockers of voltage-gated sodium channels are clinically used. Myotonia is a skeletal muscle condition characterized by the over-excitability of the sarcolemma, resulting in delayed relaxation after contraction and muscle stiffness. The therapeutic management of this disorder relies on mexiletine and other sodium channel blockers, which are not selective for the Nav1.4 skeletal muscle sodium channel isoform. Hence, the importance of deepening the knowledge of molecular requirements for developing more potent and use-dependent drugs acting on Nav1.4. Here, we review the available treatment options for non-dystrophic myotonia and the structure–activity relationship studies performed in our laboratory with a focus on new compounds with potential antimyotonic activity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MexiletineMyotoniaNAV1.4 Voltage-Gated Sodium ChannelVoltage-Gated Sodium Channel BlockersHumansMuscle, SkeletalSyndrome

Stichwörter der Autor:innen

SARmexiletinemyotoniaskeletal musclesodium channel

Substanzen

MexiletineNAV1.4 Voltage-Gated Sodium ChannelVoltage-Gated Sodium Channel Blockers

Autor:innen und Institutionen

  • Section of Pharmacology, Department of Pharmacy-Drug Sciences, University of Bari "Aldo Moro", 70125 Bari, Italy.

ORCID-Profile: Brigida Boccanegra, Paola Imbrici, Annamaria De Luca

Förderung

  • PRIN 2017
  • Ateneo Uniba
  • PRIN
  • Fondi Ateneo Uniba

Zitieren

APA

De Bellis, M., Boccanegra, B., Cerchiara, A. G., Imbrici, P., & De Luca, A. (2023). Blockers of Skeletal Muscle Nav1.4 Channels: From Therapy of Myotonic Syndrome to Molecular Determinants of Pharmacological Action and Back. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms24010857

Vancouver

De Bellis M, Boccanegra B, Cerchiara AG, Imbrici P, De Luca A. Blockers of Skeletal Muscle Nav1.4 Channels: From Therapy of Myotonic Syndrome to Molecular Determinants of Pharmacological Action and Back. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms24010857

BibTeX
@article{DeBellis2023,
  author = {De Bellis, Michela and Boccanegra, Brigida and Cerchiara, Alessandro Giovanni and Imbrici, Paola and De Luca, Annamaria},
  title = {Blockers of Skeletal Muscle Nav1.4 Channels: From Therapy of Myotonic Syndrome to Molecular Determinants of Pharmacological Action and Back},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  doi = {10.3390/ijms24010857}
}
Kostenlos starten →